新検索ページはこちら
ログイン
お問い合わせ
有効性評価に基づく前立腺がん検診ガイドライン
書誌情報
添付書類3
添付書類3-1：非採用文献リスト(A) 英文50+和文11＝61文献
| No | Auther | Title | Journal | Volumes | Issue | Pages | Year |
| A1 | Homma Y, Akaza H, Okada K, Yokoyama M, Usami M, Hirao Y, Tsushima T, Sakamoto A, Ohashi Y, Aso Y; Prostate Cancer Study Group. | Endocrine therapy with or without radical prostatectomy for T1b-T3N0M0 prostate cancer. | Int J Urol | 11 | 4 | 218-24 | 2004 |
| A2 | Namiki S, Saito S, Tochigi T, Kuwahara M, Ioritani N, Yoshimura K, Terai A, Koinuma N, Arai Y. | Impact of hormonal therapy prior to radical prostatectomy on the recovery of quality of life. | Int J Urol | 12 | 2 | 173-81 | 2005 |
| A3 | Okihara K, Nakanishi H, Nakamura T, Mizutani Y, Kawauchi A, Miki T. | Clinical characteristics of prostate cancer in Japanese men in the eras before and after serum prostate-specific antigen testing. | Int J Urol | 12 | 7 | 662-7 | 2005 |
| A4 | 北村浩二，増田健人，中村晃和，沖原宏治，浮村理，河内明宏，三木恒治． | 前立腺全摘除術を施行した検診発見前立腺がんの治療成績． | 日本がん検診・診断学会誌 | 11 | 2 | 94-7 | 2004 |
| A5 | 山本巧，伊藤一人，大井勝，武智浩之，坂西理恵，黒川公平，鈴木和浩，山中英壽． | 前立腺特異抗原(PSA)による前立腺がん検診と精度管理． | 日本がん検診・診断学会誌 | 11 | 2 | 1937-9 | 2004 |
| A6 | 平野恭弘，古瀬洋，佐藤崇，鈴木泰介，福田健，北川元昭，阿曽佳郎． | 藤枝市における前立腺癌検診8年間の結果からみた検診間隔の検討． | 日本腎泌尿器疾患予防医学研究会誌 | 12 | 1 | 38-40 | 2004 |
| A7 | 古賀寛史，山口秋人，宮崎良春，辻祐治，太田康弘，内藤誠二． | 前立腺癌PSA単独検診の問題点 ―2次検診PSA基準値未満例について― | 日本腎泌尿器疾患予防医学研究会誌 | 12 | 1 | 44-6 | 2004 |
| A8 | 北村浩二，増田健人，沖原宏治，浮村理，河内明宏，三木恒治． | 検診で発見された前立腺癌のホルモン治療成績． | 日本腎泌尿器疾患予防医学研究会誌 | 12 | 1 | 1961-2 | 2004 |
| A9 | 内藤 誠二，小藤 秀嗣，熊澤 浄一，尾本 徹男，伊東 健治，畑地 康助，清水 保夫，横山 譲二，永芳 弘之，鷺山 和幸，長谷川 淑博，森田 一喜朗，太田 康弘，箕田 薫，本村 精二． | 福岡県におけるドック前立腺検診の現状と問題点． | 日本泌尿器科学会雑誌 | 84 | 7 | 1227-35 | 1993 |
| A10 | 加藤司顯，多武保光宏，吉松正，太田雅也，金城真実，野田治久，渡辺和吉，宮田晃臣，村田明弘，三浦一郎，米田龍生，吉井将人，桶川隆嗣，小島美保，佐山孝，奴田原紀久雄，東原英二． | 前立腺癌の早期診断における検診の意義． | 日本泌尿器科学会雑誌 | 92 | 1 | 23-9 | 2001 |
| A11 | 金山博臣，香川征，宇都宮正登，川島周，武久一郎，炭谷晴雄，横関秀明． | 徳島市前立腺がん検診について(第一報) : 平成13年度初年度の結果に対する解析． | 日本泌尿器科学会雑誌 | 95 | 3 | 596-603 | 2004 |
| A12 | Madalinska JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Maas PJ, Schröder FH. | Health-related quality of life in patients with screen-detected versus clinically diagnosed prostate cancer preceding primary treatment. | Prostate | 46 | 2 | 87-97 | 2001 |
| A13 | Hugosson J, Aus G, Lilja H, Lodding P, Pihl C.G, Pileblad E. | Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable. | J Urol | 169 | 5 | 1720-3 | 2003 |
| A14 | Hugosson J, Aus G, Lilja H, Lodding P, Pihl C-G. | Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. | Cancer | 100 | 7 | 1397-405 | 2004 |
| A15 | Roobol MJ, van der Cruijsen IW, Schröder FH. | No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/ml or greater (ERSPC, Rotterdam). | Urol | 63 | 5 | 892-7 | 2004 |
| A16 | Martin E, Lujan M, Sanchez E, Herrero A, Paez A, Berenguer A. | Final results of a screening campaign for prostate cancer. | Eur Urol | 35 | 1 | 26-31 | 1999 |
| A17 | Hoedemaeker RF, Kranse R, Rietbergen JBW, Boeken Kruger AE, Schröder FH, Van der Kwast TH. | Evaluation of prostate needle biopsies in a population-based screening study: the impact of borderline lesions. | Cancer | 85 | 1 | 145-52 | 1999 |
| A18 | Crawford ED, Pinsky PF, Chia D, Kramer BS, Fagerstrom RM, Andriole G, Reding D, Gelmann EP, Levin DL, Gohagan JK. | Prostate specific antigen changes as related to the intial prostate specific antigen: date from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. | J Urol | 175 | 4 | 1286-90 | 2006 |
| A19 | Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK. | Prostate cancer screening: what we know and what we need to know. | Ann Intern Med | 119 | 9 | 914-23 | 1993 |
| A20 | Draisma G, De Koning HJ. | MISCAN: estimating lead-time and over-detection by simulation. | BJU Int | 92 | Suppl 2 | 106-11 | 2003 |
| A21 | Hugosson J, Aus G, Bergdahl S, Fernlund P, Frosing R, Lodding P, Pihl CG, Lilja H. | Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden. | BJU Int | 92 | Suppl 2 | 39-43 | 2003 |
| A22 | Postma R, Roobol M, Schroder FH, van der Kwast TH. | Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years. | Cancer | 100 | 5 | 968-75 | 2004 |
| A23 | Ito K, Yamamoto T, Ohi M, Takechi H, Kurokawa K, Suzuki K, Yamanaka H. | Cumulative probability of PSA increase above 4.0 NG/ML in population-based screening for prostate cancer. | Int J Cancer | 109 | 3 | 455-60 | 2004 |
| A24 | Steiner H, Moser P, Hager M, Berger AP, Klocker H, Spranger R, Rogatsch H, Bartsch G, Horninger W. | Clinical and pathologic features of prostate cancer detected after repeat false-negative biopsy in a screening population. | Prostate | 58 | 3 | 277-82 | 2004 |
| A25 | Nicholson PW, Harland SJ. | Survival prospects after screen-detection of prostate cancer. | BJU Int | 90 | 7 | 686-93 | 2002 |
| A26 | Lewis JS Jr, Vollmer RT, Humphrey PA. | Carcinoma extent in prostate needle biopsy tissue in the prediction of whole gland tumor volume in a screening population. | Am J Clin Pathol | 118 | 3 | 442-50 | 2002 |
| A27 | Valeri A, Cormier L, Moineau MP, Cancel-Tassin G, Azzouzi R, Doucet L, Baschet F, Cussenot I, L'Her J, Berthon P, Mangin P, Cussenot O, Morin JF, Fournier G. | Targeted screening for prostate cancer in high risk families: early onset is a significant risk factor for disease in first degree relatives. | J Urol | 168 | 2 | 483-7 | 2002 |
| A28 | Uozumi J, Tokuda Y, Fujiyama C, Takagi N, Meiri H, Kuratomi K, Nakamura K, Ichigi Y, Yoshinaga H, Kinoshita N, Masaki Z. | Annual PSA tests are not necessary for men with a PSA level below 2 ng/mL: findings of the Imari prostate cancer screening program. | Int J Urol | 9 | 6 | 334-9 | 2002 |
| A29 | Finne P, Auvinen A, Aro J, Juusela H, Maattanen L, Rannikko S, Hakama M, Tammela TL, Stenman UH. | Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination. | Eur Urol | 41 | 6 | 619-26; discussion 626-7 | 2002 |
| A30 | Makinen T, Tammela TL, Stenman UH, Maattanen L, Rannikko S, Aro J, Juusela H, Hakama M, Auvinen A. | Family history and prostate cancer screening with prostate-specific antigen. | J Clin Oncol | 20 | 11 | 2658-63 | 2002 |
| A31 | Hoedemaeker RF, van der Kwast TH, Boer R, de Koning HJ, Roobol M, Vis AN, Schroder FH. | Pathologic features of prostate cancer found at population-based screening with a four-year interval. | J Natl Cancer Inst | 93 | 15 | 1153-8 | 2001 |
| A32 | Schroder FH, Roobol-Bouts M, Vis AN, van der Kwast T, Kranse R. | Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination. | Urology | 57 | 1 | 83-90 | 2001 |
| A33 | Roberts RO, Bergstralh EJ, Lieber MM, Jacobsen SJ. | Digital rectal examination and prostate-specific antigen abnormalities at the time of prostate biopsy and biopsy outcomes, 1980 to 1997. | Urology | 56 | 5 | 817-22 | 2000 |
| A34 | Ross KS, Carter HB, Pearson JD, Guess HA. | Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. | JAMA | 284 | 11 | 1399-405 | 2000 |
| A35 | Uchida K, Takeshima H, Akaza H, Ono Y. | Screening for prostate cancer using prostate-specific antigen alone as a first-line checkup parameter: results of the health checkup system. | Jpn J Clin Oncol | 30 | 2 | 95-100 | 2000 |
| A36 | Smith DS, Carvalhal GF, Schneider K, Krygiel J, Yan Y, Catalona WJ. | Quality-of-life outcomes for men with prostate carcinoma detected by screening. | Cancer | 88 | 6 | 1454-63 | 2000 |
| A37 | Horninger W, Reissigl A, Rogatsch H, Volgger H, Studen M, Klocker H, Bartsch G. | Prostate cancer screening in Tyrol, Austria: experience and results. | Eur Urol | 35 | 5-6 | 523-38 | 1999 |
| A38 | Zappa M, Ciatto S, Bonardi R, Mazzotta A. | Overdiagnosis of prostate carcinoma by screening: an estimate based on the results of the Florence Screening Pilot Study. | Ann Oncol | 9 | 12 | 1297-300 | 1998 |
| A39 | Di Matteo L, Di Matteo R. | Does testing for prostate-specific antigen contribute to declining prostate cancer mortality? Estimating the broader economic influences on aggregate prostate cancer mortality rates. | Eur J Health Econ | 6 | 4 | 298-308 | 2005 |
| A40 | Bangma CH, Kranse R, Blijenberg BG, Schroder FH. | Free and total prostate-specific antigen in a screened population. | Br J Urol | 79 | 5 | 756-62 | 1997 |
| A41 | Helgesen F, Holmberg L, Johansson JE, Bergstrom R, Adami HO. | Trends in prostate cancer survival in Sweden, 1960 through 1988: evidence of increasing diagnosis of nonlethal tumors. | J Natl Cancer Inst | 88 | 17 | 1216-21 | 1996 |
| A42 | Parkes C, Wald NJ, Murphy P, George L, Watt HC, Kirby R, Knekt P, Helzlsouer KJ, Tuomilehto J. | Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer. | BMJ | 311 | 7016 | 1340-3 | 1995 |
| A43 | Reissigl A, Pointner J, Horninger W, Ennemoser O, Strasser H, Klocker H, Bartsch G. | Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study. | Urology | 46 | 5 | 662-5 | 1995 |
| A44 | Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB. | Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. | JAMA | 274 | 15 | 1214-20 | 1995 |
| A45 | Ciatto S, Bonardi R, Mazzotta A, Lombardi C, Santoni R, Cardini S, Zappa M. | Comparing two modalities of screening for prostate cancer: digital rectal examination + transrectal ultrasonography vs. prostate-specific antigen. | Tumori | 81 | 4 | 225-9 | 1995 |
| A46 | Gustafsson O, Theorell T, Norming U, Perski A, Ohstrom M, Nyman CR. | Psychological reactions in men screened for prostate cancer. | Br J Urol | 75 | 5 | 631-6 | 1995 |
| A47 | Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, Southwick PC. | Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. | J Urol | 152 | 6 Pt 1 | 2037-42 | 1994 |
| A48 | Van der Kwast TH, Postma R, Hoedemaeker RF, van Leenders GJ, Schroder FH. | Features of prostate cancers detected during a prevalence screening round. The Rotterdam experience. | Can J Urol | 12 | Suppl 2 | 16-20 | 2005 |
| A49 | Mettlin C, Murphy GP, Lee F, Littrup PJ, Chesley A, Babaian R, Badalament R, Kane RA, Mostofi FK. | Characteristics of prostate cancer detected in the American Cancer Society-National Prostate Cancer Detection Project. | J Urol | 152 | 5 Pt 2 | 1737-40 | 1994 |
| A50 | Bretton PR. | Prostate-specific antigen and digital rectal examination in screening for prostate cancer: a community-based study. | South Med J | 87 | 7 | 720-3 | 1994 |
| A51 | Mettlin C, Murphy GP, Lee F, Littrup PJ, Chesley A, Babaian R, Badalament R, Kane RA, Mostofi FK. | Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project. | Cancer | 72 | 5 | 1701-8 | 1993 |
| A52 | Kramer BS, Gohagan J, Prorok PC, Smart C. | A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. | Cancer | 71 | Suppl 2 | 589-93 | 1993 |
| A53 | Gerber GS, Thompson IM, Thisted R, Chodak GW. | Disease-specific survival following routine prostate cancer screening by digital rectal examination. | JAMA | 296 | 1 | 61-4 | 1993 |
| A54 | Kundu SD, Grubb RL, Roehl KA, Antenor JA, Han M, Catalona WJ. | Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml. | J Urol | 173 | 4 | 1116-20 | 2005 |
| A55 | Coory MD, Baade PD. | Urban-rural differences in prostate cancer mortality, radical prostatectomy and prostate-specific antigen testing in Australia. | Med J Aust | 182 | 3 | 112-5 | 2005 |
| A56 | Sennfalt K, Sandblom G, Carlsson P, Varenhorst E. | Costs and effects of prostate cancer screening in Sweden--a 15-year follow-up of a randomized trial. | Scand J Urol Nephrol | 38 | 4 | 291-8 | 2004 |
| A57 | Davidov O, Zelen M. | Overdiagnosis in early detection programs. | Biostatistics | 5 | 4 | 603-13 | 2004 |
| A58 | Gupta A, Roehrborn CG. | Verification and incorporation biases in studies assessing screening tests: prostate-specific antigen as an example. | Urology | 64 | 1 | 106-11 | 2004 |
| A59 | Smith RP, Malkowicz SB, Whittington R, VanArsdalen K, Tochner Z, Wein AJ. | Identification of clinically significant prostate cancer by prostate-specific antigen screening. | Arch Intern Med | 164 | 11 | 1227-30 | 2004 |
| A60 | Horninger W, Berger A, Pelzer A, Klocker H, Oberaigner W, Schonitzer D, Severi G, Robertson C, Boyle P, Bartsch G. | Screening for prostate cancer: updated experience from the Tyrol study. | Curr Urol Rep | 5 | 3 | 220-5 | 2004 |
| A61 | Gavin A, McCarron P, Middleton RJ, Savage G, Catney D, O'Reilly D, Keane PF, Murray LJ. | Evidence of prostate cancer screening in a UK region. | BJU Int | 93 | 6 | 730-4 | 2004 |
添付書類3-2：非採用文献リスト(B) 英文19+和文2＝21文献
| No | Auther | Title | Journal | Volumes | Issue | Pages | Year |
| B1 | 山本巧（群馬大学 泌尿器科），伊藤一人，大井勝，久保田裕，山中英壽 | 前立腺がん集団検診におけるPSA単独検診とPSA・直腸診併用検診の比較 | 日本がん検診・診断学会雑誌 | 8 | 2 | 63-3 | 2001 |
| B2 | 中西弘之（京都府立医科大学 泌尿器科），中尾昌宏，野本剛史，三木恒治，中川修一，北村浩二，渡辺泱 | 前立腺がん検診におけるカットオフ値としてのPSA年齢別基準値の検討 | 日本泌尿器科学会雑誌 | 90 | 11 | 853-8 | 1999 |
| B3 | Hoogendam A, Buntinx F, de Vet HC. | The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis | Family Practice | 16 | 6 | 621-6 | 1999 |
| B4 | Mäkinen T, Tammela TL, Hakama M, Stenman UH, Rannikko S, Aro J, Juusela H, Määttanen L, Auvinen A. | Tumor characteristics in a population-based prostate cancer screening trial with prostate-specific antigen | Clin Cancer Res | 9 | 7 | 2435-9 | 2003 |
| B5 | Aus G, Becker C, Franzen S, Lilja H, lodding P, Hugosson J. | Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio | Eur Urol | 45 | 2 | 160-5 | 2004 |
| B6 | De Vries SH, Postma R, Raaijmakers R, Roemeling S, Otto S, de Koning HJ, Schröder FH. | Overall and Disease-Specific Survival of Patients with Screen-Detected Prostate Cancer in the European Randomized Study of Screening for Prostate Cancer, Section Rotterdam | Eur Urol | XXX | 2006 | ||
| B7 | Rietbergen JBW, Hoedemaeker RF, Boeken Kruger AE, Kirkels WJ, Schröder FH. | The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancers in a population-based screening study. | J Urol | 161 | 4 | 1192-8 | 1999 |
| B8 | Berenguer A, Lujan M, Paez A, Santonja C, Pascual T. | The Spanish contribution to the European Randomized Study of Screening for Prostate Cancer. | BJU Int | 92 | Suppl 2 | 33-8 | 2003 |
| B9 | Quaglia A, Vercelli M, Puppo A, Casella C, Artioli E, Crocetti E, Falcini F, Ramazzotti V, Tagliabue G; Prostate Working Group. | Prostate cancer in Italy before and during the 'PSA era': survival trend and prognostic determinants. | Eur J Cancer Prev | 12 | 2 | 145-52 | 2003 |
| B10 | Ito K, Yamamoto T, Ohi M, Kurokawa K, Suzuki K, Yamanaka H. | Free/total PSA ratio is a powerful predictor of future prostate cancer morbidity in men with initial PSA levels of 4.1 to 10.0 ng/mL. | Urology | 61 | 4 | 760-4 | 2003 |
| B11 | Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schonitzer D, Severi G, Robertson C, Boyle P; Tyrol Prostate Cancer Screening Group. | Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. | Urology | 58 | 3 | 417-24 | 2001 |
| B12 | 加藤 司顯，多武保 光宏，吉松 正，太田 雅也，金城 真実，野田 治久，渡辺 和吉，宮田 晃臣，村田 明弘，三浦 一郎，米田 龍生，吉井 将人，桶川 隆嗣，小島 美保，佐山 孝，奴田原 紀久雄，東原 英二． | 前立腺癌の早期診断における検診の意義． | 日本泌尿器科学会雑誌 | 92 | 1 | 23-9 | 2001 |
| B13 | Beemsterboer PM, Kranse R, de Koning HJ, Habbema JD, Schroder FH. | Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam). | Int J Cancer | 84 | 4 | 437-41 | 1999 |
| B14 | Meyer F, Moore L, Bairati I, Fradet Y. | Quebec prostate cancer mortality dropped in 1996. | Cancer Prev Control | 2 | 4 | 163-6 | 1998 |
| B15 | Schroder FH, van der Maas P, Beemsterboer P, Kruger AB, Hoedemaeker R, Rietbergen J, Kranse R. | Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. | J Natl Cancer Inst | 90 | 23 | 1817-23 | 1998 |
| B16 | Aus G, Damber JE, Khatami A, Lilja H, Stranne J, Hugosson J. | Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. | Arch Intern Med | 165 | 16 | 1857-61 | 2005 |
| B17 | Hoedemaeker RF, Rietbergen JB, Kranse R, van der Kwast TH, Schroder FH. | Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer. | World J Urol | 15 | 6 | 339-45 | 1997 |
| B18 | Schroder FH, Raaijmakers R, Postma R, van der Kwast TH, Roobol MJ. | 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. | J Urol | 174 | 2 | 489-94; discussion 493-4 | 2005 |
| B19 | Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D, Kramer BS, Reding D, Church TR, Grubb RL, Izmirlian G, Ragard LR, Clapp JD, Prorok PC, Gohagan JK; PLCO Project Team. | Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. | J Natl Cancer Inst | 97 | 6 | 433-8 | 2005 |
| B20 | Parker C, Muston D, Melia J, Moss S, Dearnaley D. | A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. | Br J Cancer | 94 | 10 | 1361-8 | 2006 |
| B21 | Makinen T, Tammela TL, Stenman UH, Maattanen L, Aro J, Juusela H, Martikainen P, Hakama M, Auvinen A. | Second round results of the Finnish population-based prostate cancer screening trial. | Clin Cancer Res | 10 | 7 | 2231-6 | 2004 |
添付書類3-3：非採用文献リスト(C) 英文12+和文0＝12文献
| No | Auther | Title | Journal | Volumes | Issue | Pages | Year |
| C1 | de Vries SH, Raaijmakers R, Kranse R, Blijenberg BG, Schröder FH. | Prostate cancer characteristics and prostate specific antigen changes in screening detected patients initially treated with a watchful waiting policy. | J Urol | 172 | 6 Pt 1 | 2139-6 | 2004 |
| C2 | van der Cruijsen-Koeter IW, Vis AN, Roobol MJ, Wildhagen MF, de Koning HJ, van dr Kwast TH, Schröder FH. | Comparison of screen detected and clinically diagnosed prostate cancer in the European Randomised study of Screening for Prostate Cancer, section Rotterdam. | J Urol | 174 | 1 | 121-5 | 2005 |
| C3 | Roemeling S, Roobol MJ, Postma R, Gosselaar C, van der Kwast TH, Bangma CH, Schroder FH. | Management and Survival of Screen-Detected Prostate Cancer Patients who Might Have Been Suitable for Active Surveillance. | Eur Urol | 50 | 3 | 475-82 | 2006 |
| C4 | Rietbergen JWB, Boeken Kruger AE, Hoedemaeker RF, Bangma CH, Kirkels WJ, Schröder FH. | Repeat screening for prostate cancer after 1-year followup in 984 biopsied men: Clinical and pathological features of detected cancers. | J Urol | 160 | 6 Pt 1 | 2121-5 | 1998 |
| C5 | Vis AN, Boerma MO, Ciatto S, Hoedemaeker RF, Schroder FH, van der Kwast TH. | Detection of Prostate Cancer: A Comparative Study of the Diagnostic Efficacy of Sextant Transrectal versus Sextant Transperineal Biopsy. | Urol | 56 | 4 | 617-21 | 2000 |
| C6 | Gosselaar C, Roobol MJ, Roemeling S, de Vries SH, Cruijsen-Koeter I, van der Kwast TH, Schroder FH. | Screening for prostate cancer without digital rectal examination and transrectal ultrasound: results after four years in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam. | Prostate | 66 | 4 | 625-31 | 2006 |
| C7 | 渡辺真，斉藤雅人，渡邊泱． | 前立腺癌のスクリーニングにおける経直腸的超音波断層法の診断精度． | 泌尿器科紀要 | 42 | 10 | 763-6 | 1996 |
| C8 | Berger AP, Deibl M, Steiner H, Bektic J, Pelzer A, Spranger R, Klocker H, Bartsch G, Horninger W. | Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk. | Prostate | 64 | 3 | 240-5 | 2005 |
| C9 | Ciatto S, Gervasi G, Bonardi R, Frullini P, Zendron P, Lombardi C, Crocetti E, Zappa M. | Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991-1994). | Eur J Cancer | 41 | 3 | 411-5 | 2005 |
| C10 | Postma R, de Vries SH, Roobol MJ, Wildhagen MF, Schroder FH, van der Kwast TH. | Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years. | Cancer | 103 | 4 | 708-16 | 2005 |
| C11 | Brenner H, Arndt V. | Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis. | J Clin Oncol | 23 | 3 | 441-7 | 2005 |
| C12 | Roemeling S, Roobol MJ, Gosselaar C, Schroder FH. | Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). | Prostate | 66 | 10 | 1076-81 | 2006 |
